{"id":617267,"date":"2022-09-19T17:04:02","date_gmt":"2022-09-19T17:04:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=617267"},"modified":"2022-09-19T17:04:02","modified_gmt":"2022-09-19T17:04:02","slug":"dermatomyositis-market-size-growth-share-key-companies-emerging-drugs-and-forecast-2032","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/dermatomyositis-market-size-growth-share-key-companies-emerging-drugs-and-forecast-2032_617267.html","title":{"rendered":"Dermatomyositis Market Size, Growth, Share, Key Companies, Emerging Drugs and Forecast 2032"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1663580186.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Dermatomyositis Market Size, Growth, Share, Key Companies, Emerging Drugs and Forecast 2032 \" src=\"https:\/\/www.abnewswire.com\/uploads\/1663580186.jpeg\" alt=\"Dermatomyositis Market Size, Growth, Share, Key Companies, Emerging Drugs and Forecast 2032 \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Dermatomyositis Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, the Dermatomyositis Market is expected to grow in the coming years owing to the rising incidence, growing disease awareness, and the launch of promising therapies by key players such as Corbus Pharmaceuticals, CSL Behring, Provant  Therapeutics, and others.<\/div>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-market?utm_source=satPR&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\" target=\"_blank\">Dermatomyositis Market Insights Report <\/a>provides a comprehensive understanding of current treatment practices, emerging drugs, Dermatomyositis market share of individual therapies, and current and forecasted Dermatomyositis market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Highlights from the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-market?utm_source=satPR&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\" target=\"_blank\">Dermatomyositis Market Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>&nbsp;Dermatomyositis is more common in women than in men, with incidence rates being 3.98 and 4.68 per 1,000,000, respectively.<\/li>\n<li>Dermatomyositis is estimated to be around 9.63 cases per million people globally. In children, dermatomyositis symptoms commonly occur between 5 and 15 years of age.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Dermatomyositis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Dermatomyositis is a type of inflammatory myopathy characterized by inflammatory and degenerative changes in the muscles. Muscle aches, weakness, abnormality, and weakness are being observed. It may lead to a reddish-purple rash on the upper eyelids or cheeks. Symptoms include difficulty in raising the arms. There is no specific cause, for it might be due to environmental, genetic, or immunological factors.<\/p>\n<p style=\"text-align: justify;\"><strong>Dermatomyositis Treatment Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The first-line treatment of Dermatomyositis includes systemic glucocorticoids with or without immunosuppressants.&nbsp; A high dose of&nbsp; Prednisolone is given at the beginning to improve muscle strength.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Rituximab, mycophenolate, mofetil, calcineurin, and intravenous inhibitors are given to patients who do not respond positively to the first-line treatment. Second Line Therapy- involves a combination of azathioprine and methotrexate&nbsp;<\/p>\n<p style=\"text-align: justify;\">Dermatomyositis disease is also managed by general measures, physiotherapy, and medical therapy. Avoid sunlight and sun-protective clothing. Physical therapy and rehabilitation play an important role. Patients are encouraged to participate actively in exercise programs.<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the treatment options @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-market?utm_source=satPR&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Dermatomyositis Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-market?utm_source=satPR&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\" target=\"_blank\"><strong>Dermatomyositis Epidemiology Segmentation<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">The Dermatomyositis market report offers epidemiological analysis for the study period 2019-32 in the 7MM segmented into<\/p>\n<ul style=\"text-align: justify;\">\n<li>&nbsp;Dermatomyositis Total Incident Cases&nbsp;<\/li>\n<li>&nbsp;Dermatomyositis Gender-specific Incident Cases&nbsp;<\/li>\n<li>&nbsp;Dermatomyositis Subtype-specific Incident Cases&nbsp;<\/li>\n<li>&nbsp;Dermatomyositis Severity-specific Incident Cases&nbsp;<\/li>\n<li>&nbsp;Dermatomyositis Treatable Cases&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are guiding epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-market?utm_source=satPR&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Dermatomyositis Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Dermatomyositis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Study Period: 2019-32<\/li>\n<li>Coverage: TheUnitedStates, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan<\/li>\n<li>Therapeutic Assessment: Dermatomyositis off-label and emerging therapies<\/li>\n<li>Key Dermatomyositis Companies: Private, Corbus Pharmaceuticals, CSL Behring, and many others.<\/li>\n<li>Market Dynamics: Dermatomyositis market drivers and barriers&nbsp;<\/li>\n<li>Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter&#8217;s five forces, BCG Matrix, Market entry strategies.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table border=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p><strong>1.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Dermatomyositis Market Key Insights<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>2.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Dermatomyositis&nbsp; Market Report Introduction<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>3.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Dermatomyositis&nbsp; Market Overview at a Glance<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>4.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Dermatomyositis&nbsp; Market Executive Summary<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>5.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Disease Background and Overview<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>6.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Dermatomyositis Treatment and Management<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>7.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Dermatomyositis &nbsp;Epidemiology and Patient Population<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>8.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Patient Journey<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>10.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Dermatomyositis &nbsp;Emerging Drugs<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>12.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Dermatomyositis Market Outlook<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>13.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Potential of Current and Emerging Therapies<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>14.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>KOL Views<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>15.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Dermatomyositis &nbsp;&nbsp;Market Drivers<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>16.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Dermatomyositis &nbsp;&nbsp;Market Barriers<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>17.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Unmet Needs<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>18.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>SWOT Analysis<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>19.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Appendix<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>20.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>DelveInsight Capabilities<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>21.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Disclaimer<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><strong>22.<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>About DelveInsight<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=dermatomyositis-market-size-growth-share-key-companies-emerging-drugs-and-forecast-2032\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=dermatomyositis-market-size-growth-share-key-companies-emerging-drugs-and-forecast-2032\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dermatomyositis Market As per DelveInsight\u2019s assessment, the Dermatomyositis Market is expected to grow in the coming years owing to the rising incidence, growing disease awareness, and the launch of promising therapies by key players such as Corbus Pharmaceuticals, CSL Behring, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/dermatomyositis-market-size-growth-share-key-companies-emerging-drugs-and-forecast-2032_617267.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,417,406,404],"tags":[],"class_list":["post-617267","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/617267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=617267"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/617267\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=617267"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=617267"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=617267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}